SciBase submits request for payment rate to NGS


SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders,  announced today that a request for an appropriate Medicare payment assignment for the Nevisense procedure has been submitted to “National Government Services” (NGS), the Medicare Administrative Contractor with carrier jurisdiction responsibility for New York and several other states.

In July 2021, the American Medical Association (AMA) assigned a Category III CPT® code for the Nevisense melanoma detection test that has been used by providers to report the use since then.

The request was submitted to NGS based on provider usage in the New York region. NGS holds the Medicare contract for New YorkConnecticutMaineMassachusettsNew HampshireRhode IslandVermontIllinoisMinnesota and Wisconsin. A decision regarding rate assignment within NGS may be implemented in one or more of NGS jurisdictions.

“Coverage and payment from CMS are important for new procedures and technology such as ours, so this submission is an important milestone for SciBase and for Nevisense in the U.S.,” said Simon Grant, CEO of SciBase. “Establishing a payment rate with NGS represents a significant opportunity for SciBase as they cover several regions with significant potential, which would allow providers to utilize this medically necessary technology in these regions. We believe that Nevisense can play a central role in improving skin cancer detection in the U.S., and especially for the important patient demographic covered by Medicare.”

Roboticulized digests/handpicks the latest news about the artificial intelligence/machine learning industry and serves them to you daily. We provide you with the latest news and press releases straight from the AI/ML industry.